Inspira Technologies Oxy (IINN) said Friday that it is preparing to ramp up production of its Inspira ART100 respiratory device amid the recent outbreak of human metapneumovirus, or hMPV, in China.
The company said it is in talks with providers in affected regions to evaluate demand for the device and is working with suppliers to secure the components. Inspira also said it will coordinate with health authorities and "adjust its plans based on the evolving situation."
Shares of Inspira Technologies Oxy were up 13% premarket.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。